IL17A and psoriasis: Building on this approach, IL-17A blockers (secukinumab, ixekizumab) and IL-23 inhibitors (guselkumab, risankizumab) have shown remarkable success in psoriasis, psoriatic arthritis, and ankylosing spondylitis.